Skip to main content
SpringerLink
Log in

A novel gene P28GANK confers multidrug resistance by modulating the expression of MDR-1, Bcl-2, and bax in osteosarcoma cells

  • Cell Molecular Biology
  • Published:
Molecular Biology Aims and scope Submit manuscript

Abstract

As previously reported, a novel gene P28GANK conferred a multidrug resistant phenotype in gastric cancer cells. The aim of this study was to explore the role of P28GANK in the development of multidrug resistance (MDR) in osteosarcoma cells. P28GANK gene was found to be overexpressed at the mRNA level and the protein level in a cisplatin induced MDR osteosarcoma cell line Saos-2/CDDP compared to its parent cell line Saos-2. Here, we transfected the osteosarcoma cell line Saos-2 with eukaryotic expression vector of P28GANK. In vitro drug sensitivity assay suggested that Saos-2-P28GANK cells conferred resistance to both P-glycoprotein (P-gp)-related and P-gp-nonrelated drugs. Blocking P28GANK expression in MDR osteosarcoma cells Saos-2/CDDP by P28GANK-specific small interfering RNA (siRNA) increased the cell sensitivity to various chemotherapeutic drugs. Flow cytometry examination suggested that P28GANK gene expression could suppress Adriamycin-induced apoptosis accompanied by decreased accumulation and increased release of Adriamycin. Semiquantitative RT-PCR, Western blot and Luciferase reporter assay suggested that P28GANK gene could significantly up-regulate the expression of MDR-1 and Bcl-2, transcription of the MDR-1 gene and down-regulate the expression of Bax. In addition, inhibition of P28GANK expression by RNA interference or P-gp inhibition could partially reverse P28GANK-mediated MDR. Taken together, our findings suggest that down-regulation of P28GANK gene expression could sensitize osteosarcoma cells to chemotherapeutic drugs by down-regulation of the MDR-1 and Bcl-2 and up-regulation of Bax gene expression, without altering the glutathione S-transferase activity, or intracellular glutathione content in osteosarcoma cells. Further study on biological function of P28GANK may be helpful for understanding MDR mechanism of osteosarcoma and developing a strategy for osteosarcoma treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

ADR:

adriamycin

CDDP:

cisplatin

MDR:

multidrug resistance

MTX:

methotrexate

MTT:

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

P-gp:

P-glycoprotein

VCR:

vincristine

References

  1. Davis A.M., Bell R.S., Goodwin P.J. 1994. Prognostic factor in osteosarcoma: A critical review. J. Clin. Oncol. 12, 423–431.

    CAS  PubMed  Google Scholar 

  2. Link M.P., Goorin A.M., Horowitz M., Meyer W.H., Belasco J., Baker A., Ayala A., Shuster J., 1991. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity: Updated results of the Multi-Institutional Osteosarcoma Study. Clin. Orthop. 270, 8–14.

    PubMed  Google Scholar 

  3. Saeter G., Elomaa I., Wahlqvist Y., Alvegård T.A., Wiebe T., Monge O., Forrestier E., Solheim O.P. 1997. Prognostic factors in bone sarcomas. Acta Orthop. Scand Suppl. 273, 156–160.

    CAS  PubMed  Google Scholar 

  4. Bacci G., Picci P., Ferrari S., Ruggieri P., Casadei R., Tienghi A., Brach del Prever A., Gherlinzoni F., Mercuri M., Monti C. 1993. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Cancer. 72, 3227–3238.

    Article  CAS  PubMed  Google Scholar 

  5. Bramwell V.H. 1997. The role of chemotherapy in the management of nonmetastatic operable extremity osteosarcoma. Semin. Oncol. 24, 561–571.

    CAS  PubMed  Google Scholar 

  6. Bruland Ø.S., Pihl A. 1997. On the current management of osteosarcoma: A critical evaluation and a proposal for a modified treatment strategy. Eur. J. Cancer. 33, 1725–1731.

    Article  CAS  PubMed  Google Scholar 

  7. Litman T., Druley T.E., Stein W.D., Bates S.E. 2001. From MDR to MXR: New understanding of multidrug resistance systems, their properties and clinical significance. Cell. Mol. Life Sci. 58, 931–935.

    Article  CAS  PubMed  Google Scholar 

  8. Larsen A.K., Escargueil A.E., Skladanowski A. 2000. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol. Ther. 85, 217–229.

    Article  CAS  PubMed  Google Scholar 

  9. Ross D.D. 2000. Novel mechanisms of drug resistance in gastric cancer. Gastric Cancer. 14, 467–473.

    CAS  Google Scholar 

  10. Fan D., Zhang X., Chen X. 2005, Bird’s-eye view on gastric cancer research of the past 25 years. J. Gastroenterol. Hepatol. 20(3), 360–365.

    Article  PubMed  Google Scholar 

  11. Narasaki F., Oka M., Nakano R., Ikeda K., Fukuda M., Nakamura T., Soda H., Nakagawa M., Kuwano M., Kohno S. 1997. Human canalicular multispecific organic anion transporter (cMOAT) is expressed in human lung, gastric, and colorectal cancer cells. Biochem. Biophys. Res. Commun. 240, 606–611.

    Article  CAS  PubMed  Google Scholar 

  12. Nakamura T., Oka M., Aizawa K., Soda H., Fukuda M., Terashi K., Ikeda K., Mizuta Y., Noguchi Y., Kimura Y., Tsuruo T., Kohno S. 1999. Direct interaction between a quinoline derivative, MS-209, and multidrug resistance protein (MRP) in human gastric cancer cells. Biochem. Biophys. Res. Commun. 255, 618–624.

    Article  CAS  PubMed  Google Scholar 

  13. Tomonaga M., Oka M., Narasaki F., Fukuda M., Nakano R., Takatani H., Ikeda K., Terashi K., Matsuo I., Soda H., Cowan K.H., Kohno S. 1996. The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers. Jpn. J. Cancer Res. 87, 1263–1270.

    CAS  PubMed  Google Scholar 

  14. Johnstone R.W., Ruefli A.A., Lowe S.W. 2002. Apoptosis: A link between cancer genetics and chemotherapy. Cell. 108, 153–164.

    Article  CAS  PubMed  Google Scholar 

  15. Inoue S., Salah-Eldin A.E., Omoteyama K. 2001. Apoptosis and anticancer drug resistance. Hum. Cell. 14, 211–221.

    CAS  PubMed  Google Scholar 

  16. Shibuya H., Kato Y., Saito M., Isobe T., Tsuboi R., Koga M., Toyota H., Mizuguchi J. 2003. Induction of apoptosis and/or necrosis following exposure to antitumour agents in a melanoma cell line, probably through modulation of Bcl-2 family proteins. Melanoma Res. 13, 457–464.

    Article  CAS  PubMed  Google Scholar 

  17. Grossman D., Altieri D.C. 2001. Drug resistance in melanoma: Mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev. 20, 3–11.

    Article  CAS  PubMed  Google Scholar 

  18. Park T.J., Kim H.S., Byun K.H., Jang J.J., Lee Y.S., Lim I.K. 2001. Sequential changes in hepatocarcinogenesis induced by diethylnitrosamine plus thioacetamide in Fischer 344 rats: Induction of gankyrin expression in liver fibrosis, pRB degradation in cirrhosis, and methylation of p16(INK4A) exon 1 in hepatocellular carcinoma. Mol. Carcinogen. 30, 138–150.

    Article  CAS  Google Scholar 

  19. Li J., Tsai M.D. 2002. Novel insights into the INK4-CDK4/6-Rb pathway: Counter action of gankyrin against INK4 proteins regulates the CDK4-mediated phosphorylation of Rb. Biochemistry. 41, 3977–3983.

    Article  CAS  PubMed  Google Scholar 

  20. Li X., Zhang Y., Xiong C., Jin H., Jing B., Zhang Y., Fan D. 2009. Overexpression of a new gene P28GANK confers multidrug resistance of gastric cancer cells. Cancer Invest. 27(2), 129–139.

    Article  CAS  PubMed  Google Scholar 

  21. Li H., Fu X., Chen Y., Hong Y., Tan Y., Cao H., Wu M., Wang H. 2005. Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma. Gastroenterology. 128, 2029–2041.

    Article  CAS  PubMed  Google Scholar 

  22. Lazarova D.L., Bordonaro M., Sartorelli A.C. 2001. Transcriptional regulation of the vitamin D3 receptor gene by ZEB. Cell Growth Differ. 12, 319–326.

    CAS  PubMed  Google Scholar 

  23. Perkins C.L., Fang G., Kim C.N., Bhalla K. N. 2000. The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res. 60, 1645–1653.

    CAS  PubMed  Google Scholar 

  24. Bacci G., Ferrari S., Bertoni F., Ruggieri P., Picci P., Longhi A., Casadei R., Fabbri N., Forni C., Versari M., Campanacci M. 2000. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 protocol: An updated report. J. Clin. Oncol. 18, 4016–4027.

    CAS  PubMed  Google Scholar 

  25. Baldini N., Scotlandi K., Barbanti-Bròdano G., Manara M.C., Maurici D., Bacci G., Bertoni F., Picci P., Sottili S., Campanacci M., Massimo S. 1995. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N. Engl J. Med. 333, 1380–1385.

    Article  CAS  PubMed  Google Scholar 

  26. Bramwell V.H.C. 2000. Osteosarcomas and other cancers of bone. Curr. Opin. Oncol. 12, 330–336.

    Article  CAS  PubMed  Google Scholar 

  27. Serra M., Scotlandi K., Reverter-Branchat G., Ferrari S., Manara M.C., Benini S., Incaprera M., Bertoni F., Mercuri M., Briccoli A., Bacci G., Picci P. 2003. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J. Clin. Oncol. 21, 536–542.

    Article  CAS  PubMed  Google Scholar 

  28. Wandel C., Kim R.B., Kajiji S., Peter Guengerich F., Wilkinson G., Wood A. 1999. P-glycoprotein and cytochrome P-450 3A inhibition: Dissociation of inhibitory potencies. Cancer Res. 59, 3944–3948.

    CAS  PubMed  Google Scholar 

  29. Agrawal M., Abraham J., Balis F.M., Edgerly M., Stein W.D., Bates S., Fojo T., Chen C.C. 2003. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin. Cancer Res. 9, 650–656.

    CAS  PubMed  Google Scholar 

  30. Naito M., Matsuba Y., Sato S., Hirata H., Tsuruo T. 2002. MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models. Clin. Cancer Res. 8, 582–588.

    PubMed  Google Scholar 

  31. Sinicrope F.A., Dudeja P.K., Bissonnette B.M., Safa A.R., Brasitus T.A. 1992. Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles. J. Biol. Chem. 15, 24995–245002.

    Google Scholar 

  32. Gaitanos T.N., Buey R.M., Díaz J.F., Northcote P.T., Teesdale-Spittle P., Andreu J.M., Miller J.H. 2004. Peloruside A does not bind to the taxoid site on h-tubulin and retains its activity in multidrug-resistant cell lines. Cancer Res. 64, 5063–5067.

    Article  CAS  PubMed  Google Scholar 

  33. Cabot M.C., Giuliano A.E., Han T.Y., Liu Y.Y. 1999. SDZ PSC 833, the Cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells. Cancer Res. 59, 880–885.

    CAS  PubMed  Google Scholar 

  34. Potocnik U., Glavac M.R., Golouh R., Glavac D. 2001. The role of P-glycoprotein (MDR1) polymorphisms and mutations in colorectal cancer. Pflugers Arch. 442, 182–183.

    Article  Google Scholar 

  35. Igney F.H., Krammer P.H. 2002. Death and anti-death: Tumour resistance to apoptosis. Nature Rev. Cancer. 2, 277–288.

    Article  CAS  Google Scholar 

  36. Oltvai Z.N., Milliman C.L., Korsmeyer S.J. 1993. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74, 609–619.

    Article  CAS  PubMed  Google Scholar 

  37. Reed J.C. 1999. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 17, 2941–2953.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Orthopedic Oncology, Tianjin Cancer Institute, Hospital, Tianjin Medical University, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Huanhuxi Road, Hexi District, Tianjin, 300060, China

    Guowen Wang & Jian Duo

  2. Department of Orthopedic Oncology, The Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Nangang District, Harbin, 150086, China

    Jiesheng Rong & Zhihong Zhou

Authors
  1. Guowen Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jiesheng Rong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhihong Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jian Duo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guowen Wang.

Additional information

The article is published in the original.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, G., Rong, J., Zhou, Z. et al. A novel gene P28GANK confers multidrug resistance by modulating the expression of MDR-1, Bcl-2, and bax in osteosarcoma cells. Mol Biol 44, 898–906 (2010). https://doi.org/10.1134/S0026893310060063

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S0026893310060063

Keywords

Search

Navigation